Data / Form D filings / Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd.: Form D filings
Chemomab Therapeutics Ltd., a biotechnology company in Tel Aviv, Israel, filed 2 Form D notices with the SEC between 2021 and 2024. The latest, on August 9, 2024, reports $10 million sold of a $10 million offering to 10 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- KIRYAT ATIDIM, BUILDING 7, Tel Aviv, Israel, 61580
- Phone
- 972-77-331-0156
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Israel
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1534248
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 9, 2024 | New notice | $10,000,000 | $10,000,000 | 10 | Jul 29, 2024 | sec.gov | |
| Mar 30, 2021 | New notice | $45,446,544 | $45,446,544 | 26 | Mar 16, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Neil Harris Cohen | Director | |
| Jill Harris Quigley | Director | |
| Sigal Fattal | Executive Officer | |
| Adi Mor | Executive Officer, Director | |
| Alan Charles Moses | Director | |
| Matthew Frankel | Executive Officer | |
| Claude Charles Nicaise | Director | |
| Nissim Darvish | Director |
Every Form D from the week of Aug 5, 2024 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Chemomab Therapeutics Ltd. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.